SENBEXUS Trademark

Trademark Overview

On Wednesday, April 22, 2020, a trademark application was filed for SENBEXUS with the United States Patent and Trademark Office. The USPTO has given the SENBEXUS trademark a serial number of 88882830. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 9, 2024. This trademark is owned by Celgene Corporation. The SENBEXUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pha...
senbexus

General Information

Serial Number88882830
Word MarkSENBEXUS
Filing DateWednesday, April 22, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 9, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 8, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 1, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Saturday, April 25, 2020NEW APPLICATION ENTERED
Friday, May 1, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 13, 2020ASSIGNED TO EXAMINER
Tuesday, July 14, 2020NON-FINAL ACTION WRITTEN
Tuesday, July 14, 2020NON-FINAL ACTION E-MAILED
Tuesday, July 14, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 11, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 11, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 11, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 12, 2021ASSIGNED TO EXAMINER
Tuesday, January 19, 2021TEAS PETITION TO REVIVE RECEIVED
Tuesday, January 19, 2021PETITION TO REVIVE-GRANTED
Tuesday, January 19, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 20, 2021NOTICE OF REVIVAL - E-MAILED
Monday, May 3, 2021ASSIGNED TO LIE
Tuesday, May 4, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 4, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 5, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 19, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 8, 2021PUBLISHED FOR OPPOSITION
Tuesday, June 8, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 3, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 2, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, February 2, 2022SOU EXTENSION 1 FILED
Wednesday, February 2, 2022SOU EXTENSION 1 GRANTED
Friday, February 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 27, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, July 27, 2022SOU EXTENSION 2 FILED
Wednesday, July 27, 2022SOU EXTENSION 2 GRANTED
Friday, July 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 31, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, January 31, 2023SOU EXTENSION 3 FILED
Tuesday, January 31, 2023SOU EXTENSION 3 GRANTED
Thursday, February 2, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 2, 2023SOU EXTENSION 4 FILED
Wednesday, August 2, 2023SOU EXTENSION 4 GRANTED
Friday, August 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 12, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 12, 2024SOU EXTENSION 5 FILED
Tuesday, January 30, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, January 31, 2024SOU EXTENSION 5 GRANTED
Thursday, February 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 9, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, September 9, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

senbexus diseases pharmaceutical human preparations disorders cancer immune namely anti system